KeyBanc Upgrades BrightSpring Health (BTSG) to Overweight

KeyBanc analyst Matthew Gillmor upgraded BrightSpring Health (NASDAQ: BTSG) from Sector Weight to Overweight with a price target of $45.00.

The analyst comments: "We recently hosted meetings with BTSG management in Louisville. We came away with a deeper appreciation for BTSG's competitive positioning in Specialty Pharmacy and sustainability of EBITDA growth. While the stock has had an impressive YTD run, we think EBITDA estimates for 2026-2027 will continue to migrate higher, supported by LDD wins, generic conversions, operational initiatives, and the pending AMED deal. Our $45 price target is based on a 13.5x multiple on our 2027E, and we think valuation carries an upward bias given the EBITDA growth trajectory."

For an analyst ratings summary and ratings history on BrightSpring Health click here. For more ratings news on BrightSpring Health click here.

Shares of BrightSpring Health closed at $35.90 yesterday.

You May Also Be Interested In

• Quantinuum (QNT) opens at $68, 13% above IPO pricing
• Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
• Fed's Schmid: inflation is too high; it has been a five year fight and the Fed is still trying to figure it out